Pharmacogenomics of third-generation aromatase inhibitors

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 9, 2012, Pages 1299-1307

  Turkistani, Abdullah ^a   Marsh, Sharon ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anastrozole; CYP19A1; Exemestane; Letrozole; Pharmacogenomics; Polymorphism

Indexed keywords

ANASTROZOLE; AROMATASE; CYTOCHROME P450 3A4; CYTOCHROME P450 4A11; EXEMESTANE;

ARTHRALGIA; BREAST CANCER; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; GENE DELETION; GENETIC VARIABILITY; GLUCURONIDATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHARMACOGENOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ANIMALS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; GENOTYPE; HUMANS; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84861392012     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.687721     Document Type: Review

References (56)

1. Breast cancer statistics. American Cancer Society. Available from: www.cancer.org [Last accessed 1 March 2012]
2. Breast cancer statistics. Canadian Cancer Society. Available from: www.cancer.ca [Last accessed 1 March 2012]
3. Bulun SE, Takayama K, Suzuki T, et al. Organization of the human aromatase p450 (CYP19) gene. Semin Reprod Med 2004;22:5-9
4. Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol 2001;45:S116-24
5. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86:225-30
6. Brodie A, Inkster S. Aromatase in the human testis. J Steroid Biochem Mol Biol 1993;44:549-55
7. Larionov AA, Vasyliev DA, Mason JI, et al. Aromatase in skeletal muscle. J Steroid Biochem Mol Biol 2003;84:485-92
8. Sasano H, Uzuki M, Sawai T, et al. Aromatase in human bone tissue. J Bone Miner Res 1997;12:1416-23
9. Sawaya ME, Penneys NS. Immunohistochemical distribution of aromatase and 3B-hydroxysteroid dehydrogenase in human hair follicle and sebaceous gland. J Cutan Pathol 1992;19:309-14
10. Bulun SE, Sharda G, Rink J, et al. Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. J Clin Endocrinol Metab 1996;81:1273-7
11. Thompson EA Jr, Siiteri PK. Subcellular distribution of aromatase in human placenta and ovary. Horm Res 1979;11:179-85
12. Biegon A, Kim SW, Alexoff DL, et al. Unique distribution of aromatase in the human brain: in vivo studies with PET and [N-methyl-11C] vorozole. Synapse 2010;64:801-7
13. Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 2004;9:126-36
14. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23:1616-22
15. Ingle JN. Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention. Oncology (Williston Park) 2001;15:28-34
16. Colleoni M, Gelber S, Goldhirsch A, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: international Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006;24:1332e41
17. Rugo HS. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 2008;19:16-27
18. Lazarus P, Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. Drug Metab Rev 2010;42:182-94
19. Evans TR, Di Salle E, Ornati G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992;52:5933-9
20. Yates RA, Dowsett M, Fisher GV, et al. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996;73:543-8
21. Lipton A, Demers LM, Harvey HA, et al. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 1995;75:2132-8
22. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007;18(Suppl 8):26-35
23. Mouridsen HT. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Curr Med Res Opin 2006;22:1609-21
24. Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 2011;13:205
25. Bundred NJ. The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer 2005;93:23-7
26. Gonnelli S, Petrioli R. Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer. Clin Interv Aging 2008;3:647-57
27. Santoro S, Santini M, Pepe C, et al. Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. J Eur Acad Dermatol Venereol 2011;25:596-8
28. Muslimani AA, Spiro TP, Chaudhry AA, et al. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms? Clin Breast Cancer 2009;9:34-8
29. Ingle JN. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 2008;112:695-9
30. Weinshilboum R. Pharmacogenomics of endocrine therapy in breast cancer. Adv Exp Med Biol 2008;630:220-31
31. Ma CX, Adjei AA, Salavaggione OE, et al. Human aromatase: gene resequencing and functional genomics. Cancer Res 2005;65:11071-82
32. Higgins MJ, Stearns V. Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 2011;62:281-93
33. Kamdem LK, Liu Y, Stearns V, et al. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol 2010;70:854-69
34. Ingle JN, Buzdar AU, Schaid DJ, et al. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res 2010;70:3278-86
35. Wiener D, Fang JL, Dossett N, Lazarus P. Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone glucuronidation phenotype in human liver microsomes. Cancer Res 2004;64:1190-6
36. Ehmer U, Vogel A, Schutte JK, et al. Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP- glucuronosyltransferase UGT1A4. Hepatology 2004;39:970-7
37. Kamdem LK, Flockhart DA, Desta Z. In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos 2011;39:98-105
38. Sachse C, Bhambra U, Smith G, et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 2003;55:68-76
39. Napoli N, Villareal DT, Mumm S, et al. Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res 2005;20:232-9
40. Keshava C, McCanlies EC, Weston A. CYP3A4 polymorphisms - potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol 2004;160:825-41
41. Cho BH, Park BL, Kim LH, et al. Highly polymorphic human CYP4A11 gene. J Hum Genet 2005;50:259-63
42. Mikhailova ON, Gulyaeva LF, Prudnikov AV, et al. Estrogen-metabolizing gene polymorphisms in the assessment of female hormone-dependent cancer risk. Pharmacogenomics J 2006;6:189-93
43. Sun D, Chen G, Dellinger RW, et al. Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. Pharmacogenet Genomics 2010;20:575-85
44. Wilson W III, Pardo-Manuel de Villena F, Lyn-Cook BD, et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004; 84:707-14
45. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003;197:1279-8
46. Jeong S, Woo MM, Flockhart DA, Desta Z. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanolbisbenzonitrile in vitro. Cancer Chemother Pharmacol 2009;64:867-75
47. Murai K, Yamazaki H, Nakagawa K, et al. Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica 2009;39:795-802
48. Desta Z, Kreutz Y, Nguyen AT, et al. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther 2011;90:693-700
49. Colomer R, Monzo M, Tusquets I, et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008;14:811-16
50. Garcia-Casado Z, Guerrero-Zotano A, Llombart-Cussac A, et al. A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer 2010;10:36
51. Fasching PA, Loehberg CR, Strissel PL, et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/ neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat 2008;112:89-98
52. Wang L, Ellsworth KA, Moon I, et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 2010;70:319-28
53. Mao JJ, Su HI, Feng R, et al. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 2011;13:R8
54. Haiman CA, Hankinson SE, Spiegelman D, et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 2000;87:204-10
55. Zarrabeitia MT, Hernandez JL, Valero C, et al. A common polymorphism in the 5'-untranslated region of the aromatase gene influences bone mass and fracture risk. Eur J Endocrinol 2004;150:699-704
56. Ingle JN, Schaid DJ, Goss PE, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010;28:4674-82